Clinical Trials on Ability, Spatial in Australia

Total 40 results

Supernus Pharmaceuticals, Inc.
Melbourne Health

Completed

Bioavailability, Safety, and Tolerability of BIS-001 ER

Epilepsy, Complex Partial

Australia
ZimVie

Completed

Study of Certain Prevail Implants Used to Treat All Types of Edentulism in the Maxilla and Mandible (PrevailMulti)

Partial Edentulism

Austria
Medical University Innsbruck

Completed

The Influence of Wedge Insoles After Partial Meniscectomy

Partial Meniscectomy

Austria
Johannes Kepler University of Linz
Kepler University Hospital

Recruiting

Core Strength and Coordinative Skills

Physical Fitness | Postural Balance | Core Stability | Core Strength

Austria
Medical University of Vienna

Recruiting

Effect of Face Masks on Pulmonary Function in Patients With COPD

COPD | Walking, Difficulty

Austria
Medical University of Vienna

Completed

Effect of Shock Waves on Dental Parameters

Blood Flow | Tooth Stability

Austria
Genovate-NaviFUS (Australia) Pty Ltd.
Genovate Biotechnology Co., Ltd.,; NaviFUS Corporation

Recruiting

Evaluation of the NaviFUS System in Drug Resistant Epilepsy

Drug Resistant Epilepsy | Epilepsy, Temporal Lobe

Australia
Medical University of Vienna

Unknown

Study in an Ex-vivo Thrombosis Model With Human Umbilical Vein Endothelial Cells (HUVEC)-Perfusion (HUVEC)

Thrombosis | Thrombus Formation | Thrombus Stability

Austria
Pfizer

Completed

Evaluation of Long-Term Safety and Efficacy of Pregabalin in Patients With Partial Seizures.

Seizure Disorder, Partial

Australia, Spain, Portugal, United Kingdom, Canada, Belgium, Germany, Poland, Netherlands, Austria
Pfizer

Completed

To Evaluate Long-Term Safety and Efficacy of Pregabalin in Patients With Partial Seizures.

Seizure Disorder, Partial

Spain, France, Italy, Australia, United Kingdom, Germany, Belgium, Netherlands, Austria, Sweden, Finland, South Africa, Switzerland
UCB Pharma

Terminated

Hormonal and Lipid Levels in Male Subjects After a Switch From Carbamazepine to Lacosamide (VICTOR)

Epilepsy, Partial

Austria, Germany, Spain
Medical University of Vienna

Completed

Effect of Shock Waves on Tooth Movement and Miniscrew Stability

Mesial Movement of Teeth | Miniscrew Stability

Austria
Institut Straumann AG

Completed

Evaluation of Immediate Versus Delayed Loading of Dental Implants With a Modified Surface

Partial Edentulism

United States, Austria, Germany, Ireland, Netherlands, Portugal, Spain, Sweden, Switzerland
Cerebral Therapeutics LLC

Terminated

Anti-Epilepsy Medication Valproate Administered Via ICV Route and Catheters and Pumps for CSF Infusion

Focal Epilepsy

Israel, Australia
Bial - Portela C S.A.

Completed

Eslicarbazepine Acetate (BIA 2 093) as Therapy for Refractory Partial Seizures in Children

Partial Epilepsy in Children and Adolescents

United Kingdom, Spain, Serbia, Italy, Austria, Bosnia and Herzegovina, Croatia, Czechia, France, Germany, Hungary, Malaysia, Moldova, Republic of, Philippines, Poland, Portugal, Romania, Russian Federation, Slovakia, Taiwan, Ukr...
Pfizer

Completed

Pregabalin Open-Label Extension Trial in Patients With Partial Seizures

Epilepsies, Partial | Epilepsy, Complex Partial

Spain, France, Canada, Germany, Italy, Lithuania, Austria, United Kingdom
Eisai Inc.

Completed

A Double-blind Study to Compare the Efficacy and Safety of Zonisamide and Carbamazepine as Monotherapy, in Newly Diagnosed Partial Epilepsy

Epilepsy

Australia, France, Poland, Germany, Spain, India, Serbia, Greece, Korea, Republic of, Russian Federation, Taiwan, Hungary, Italy, Sweden, Denmark, Slovakia, United Kingdom, South Africa
UCB Pharma

Completed

Trial to Assess Lacosamide as the First add-on Anti-epileptic Drug Treatment in Patients With Partial-onset Seizures

Partial Epilepsies

United States, Austria, Bulgaria, Czechia, Denmark, Finland, France, Greece, Italy, Mexico, Romania, Russian Federation, Spain, Switzerland, Turkey
SK Life Science, Inc.

Recruiting

Safety and Efficacy Study of Cenobamate in Pediatric Subjects 2-17 Years of Age With Partial-onset (Focal) Seizures

Partial Epilepsy

United States, Spain, Korea, Republic of, Germany, Australia, Poland, Hungary
UCB Pharma

Completed

Assess Safety and Efficacy of Lacosamide in Patients With Partial Seizures

Epilepsy

France, Poland, United Kingdom, Germany, Spain, Finland, Australia, Russian Federation, Hungary, Lithuania, Sweden, Czechia, Croatia
SK Life Science, Inc.

Completed

A Double-Blind, Randomized, Placebo-Controlled, Phase 2 Trial of YKP3089 as Adjunctive Therapy in Subjects With Partial Onset Seizures

Partial Epilepsy

Australia, United States, Korea, Republic of, Germany, Hungary, Serbia, Bulgaria, Czechia, France, Israel, Poland, Romania, Spain, Thailand, Ukraine
SK Life Science, Inc.

Completed

Safety and Pharmacokinetic Study of YKP3089 as Adjunctive Therapy in Subjects With Partial Onset Seizures

Partial Epilepsy

United States, Spain, Korea, Republic of, Serbia, Germany, Bulgaria, Argentina, Australia, Chile, Czechia, Hungary, Mexico, Poland, Russian Federation, Sweden, Thailand, Ukraine
Marinus Pharmaceuticals

Completed

Phase 3 Study of Adjunctive Ganaxolone in Adults With Drug-resistant Partial Onset Seizures and Open-label Extension

Drug Resistant Partial Onset Seizure

United States, Australia, Russian Federation, Bulgaria, Germany, Poland
NYU Langone Health
The Epilepsy Study Consortium

Completed

The Human Epilepsy Project (HEP)

Focal Epilepsy

United States, Canada, Australia
Novartis

Withdrawn

Evaluate the Efficacy of BGG492 as Adjunctive Treatment in Patients With Refractory Partial Onset Seizures

Partial Onset Seizures

United States, Austria, Spain, Estonia, Bulgaria, Latvia, Canada, India, Belgium, Lithuania, Romania
Johnson & Johnson Pharmaceutical Research & Development...

Completed

Topiramate as Adjunctive Therapy in Infants 1-24 Months for the Control of Partial Onset Seizures

Epilepsy | Seizures | Partial Seizure Disorder

United States, Australia, France, Belgium, Taiwan, Spain, Argentina, Poland, India, Ukraine, Finland, Korea, Republic of, Russian Federation, Chile, Thailand, Hungary, Israel, New Zealand, Canada, Mexico, Norway, Netherlands, South...
Eisai Inc.

Completed

Evaluating Efficacy and Safety of E2007 (Perampanel) Given as Adjunctive Therapy in Subjects With Refractory Partial Seizures

Refractory Partial Seizures

Hong Kong, Italy, Australia, Spain, Portugal, Taiwan, India, Thailand, Hungary, Poland, Bulgaria, Serbia, Russian Federation, Korea, Republic of, Ukraine, Romania, Latvia, Lithuania, Germany, Estonia, Czech Republic, Philippines, Ma...
Eisai Inc.

Completed

A Post-marketing Observational Study Of The Use Of Zonisamide (ZNS) in the Adjunctive Treatment Of Adult Patients With Partial Onset Seizures (Study E2090-E044-410) (ZOOM)

Partial Onset Seizures

Germany, Sweden, Norway, Austria, Denmark
Eisai Inc.

No longer available

An Extended Access Program for Perampanel

Partial Onset Seizures

Italy, Spain, Belgium, Israel, Poland, Taiwan, Czechia, Finland, Thailand, Malaysia, Argentina, Chile, Canada, Hungary, Australia, Lithuania, Latvia, Estonia, Netherlands, Greece, Hong Kong
Eisai Inc.

Completed

Assessing The Long-Term Safety And To Explore The Long-Term Efficacy Of Zonisamide As Monotherapy In Newly Diagnosed Partial Seizures

Epilepsy

Greece, Italy, Spain, Sweden, Korea, Republic of, Germany, Australia, France, Switzerland, Slovakia, Poland, Taiwan, Hungary, Serbia, India, United Kingdom, Denmark, Russian Federation, South Africa, Montenegro
Eisai Co., Ltd.

Completed

A Study With an Open-label Extension Phase to Evaluate the Efficacy and Safety of Perampanel (E2007) Administered as an Adjunctive Therapy in Subjects With Refractory Partial-onset Seizures

Partial-onset Seizures

Korea, Republic of, Japan, Australia, China, Malaysia, Taiwan, Thailand
Eisai Inc.

Completed

To Evaluate The Efficacy and Safety of E2007 (Perampanel) Given as Adjunctive Therapy in Subjects With Refractory Partial Seizures

Refractory Partial Seizures

United States, France, Germany, Italy, United Kingdom, Belgium, Israel, South Africa, Finland, Russian Federation, Austria, Netherlands, Sweden, India
UCB Pharma GmbH

Completed

Study Evaluating Changes in Total Drug Load and Seizure Frequency Using Vimpat® (Lacosamide) in Combination Therapy (VICTOS)

Focal Epilepsy With and Without Secondary Generalization

Germany, Austria
Sanford Health
National Ataxia Foundation; Beyond Batten Disease Foundation; Pitt Hopkins Research... and other collaborators

Recruiting

Rare Disease Patient Registry & Natural History Study - Coordination of Rare Diseases at Sanford (CoRDS)

Mitochondrial Diseases | Retinitis Pigmentosa | Myasthenia Gravis | Eosinophilic Gastroenteritis | Multiple System Atrophy | Leiomyosarcoma | Leukodystrophy | Anal Fistula | Spinocerebellar Ataxia Type 3 | Friedreich Ataxia | Kennedy Disease | Lyme Disease | Hemophagocytic Lymphohistiocytosis | Spinocerebellar Ataxia... and other conditions

United States, Australia
UCB Biopharma SRL

Active, not recruiting

A Study to Test the Efficacy, Safety, and Pharmacokinetics of Rozanolixizumab in Adult Study Participants With Leucine-Rich Glioma Inactivated 1 Autoimmune Encephalitis

Leucine-Rich Glioma Inactivated 1 Autoimmune Encephalitis

United States, Australia, Belgium, France, Germany, Italy, Netherlands, Spain, United Kingdom
University of California, San Francisco
National Institute of Neurological Disorders and Stroke (NINDS)

Completed

Epilepsy Phenome/Genome Project (EPGP)

Epilepsy | Infantile Spasms | Lennox-Gastaut Syndrome | Polymicrogyria | Localization-related Epilepsy | Periventricular Heterotopias

United States, Argentina, Australia
Hoffmann-La Roche
Chugai Pharmaceutical Co.

Recruiting

A Study To Evaluate The Efficacy, Safety, Pharmacokinetics, And Pharmacodynamics Of Satralizumab In Patients With Anti-N-Methyl-D-Aspartic Acid Receptor (NMDAR) Or Anti-Leucine-Rich Glioma-Inactivated 1 (LGI1) Encephalitis (Cielo)

NMDAR Autoimmune Encephalitis | LGI1 Autoimmune Encephalitis

United States, Korea, Republic of, China, Japan, Czechia, Italy, Poland, Austria, Brazil, Argentina, Netherlands, Taiwan, France, Denmark, Ghana
ppharmaand GmbH
Bristol-Myers Squibb; Gynecologic Oncology Group; European Network of Gynaecological... and other collaborators

Active, not recruiting

A Study in Ovarian Cancer Patients Evaluating Rucaparib and Nivolumab as Maintenance Treatment Following Response to Front-Line Platinum-Based Chemotherapy (ATHENA)

Fallopian Tube Cancer | Epithelial Ovarian Cancer | Primary Peritoneal | Newly Diagnosed | FIGO Stage III-IV | Partial Response | Complete Response

United States, United Kingdom, Korea, Republic of, Russian Federation, Canada, Denmark, Taiwan, New Zealand, Ireland, Japan, Spain, Australia, Israel, Italy, Greece, Sweden, Czechia, Finland, Poland, Belgium, Germany, Romania, Singa... and more
AstraZeneca
Merck Sharp & Dohme LLC; European Network of Gynaecological Oncological Trial... and other collaborators

Active, not recruiting

Olaparib Treatment in BRCA Mutated Ovarian Cancer Patients After Complete or Partial Response to Platinum Chemotherapy

Relapsed Ovarian Cancer | Following Complete or Partial Response to Platinum Based Chemotherapy | Platinum Sensitive | BRCA Mutated

Korea, Republic of, France, China, Italy, United States, Israel, United Kingdom, Canada, Japan, Germany, Brazil, Netherlands, Belgium, Poland, Australia, Russian Federation, Spain
AstraZeneca
Merck Sharp & Dohme LLC; GOG Foundation; Myriad Genetic Laboratories, Inc.

Active, not recruiting

Olaparib Maintenance Monotherapy in Patients With BRCA Mutated Ovarian Cancer Following First Line Platinum Based Chemotherapy. (SOLO-1)

Advanced Ovarian Cancer | Newly Diagnosed | FIGO Stage III-IV | Partial Response | Complete Response | BRCA Mutation | First Line Platinum Chemotherapy

Korea, Republic of, France, Italy, United States, Israel, Canada, China, Brazil, United Kingdom, Poland, Australia, Japan, Netherlands, Russian Federation, Spain

Clinical Trials on Ability, Spatial in Australia

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in China

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations